Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system

Immunology

Volumn 103, Issue 1, 2001, Pages 98-105

  Ara, Yuki ^a   Saito, Tomoyuki ^a   Takagi, Toshitaka ^a   Hagiwara, Eri ^a   Miyagi, Yohei ^a   Sugiyama, Mitsugu ^a   Kawamoto, Susumu ^a   Ishii, Norihisa ^b   Yoshida, Takuji ^a   Hanashi, Daisuke ^a   Koshino, Tumihisa ^a   Okada, Hidechika ^c   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A; PROTEIN ANTIBODY; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENZYME INDUCTION; FEMALE; HELPER CELL; HEMAGGLUTINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; COMPLEMENT ACTIVATION; CYTOKINES; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED AKR; MICE, INBRED BALB C; MUSCLE, SKELETAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; ZYMOSAN;

EID: 0035014397     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01201.x     Document Type: Article

References (42)

1. Hassett DE, Whitton JL. DNA immunization. Trends Microbiol 1996; 4:307-12.
2. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1) - specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177:249-56.
3. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM. A strategy for prophylactic vaccination against HIV. Science 1993; 260:1270-2.
4. Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995; 1:59-64.
5. Okuda K, Bukawa H, Hamajima K et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses 1995; 11:933-43.
6. Pillemer L, Ecker EE. Anticomplementary factor in fresh yeast. J Biol Chem 1941; 137:139-42.
7. Czop JK, Fearon DT, Austen KF. Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. J Immunol 1978; 120:1132-8.
8. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 1984; 132:3034-40.
9. Czop JK. The role of β-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation, Pathol Immunopathol Res 1986; 5:286-96.
10. Czop JK, Austen KF. Generations of leukotrienes by human monocytes upon stimulation of their β-glucan receptor during phagocytosis. Proc Natl Acad Sci USA 1985; 82:2751-5.
11. Czop JK, Puglisi AV, Miorandi DZ, Austen KF, Perturbation of β-glucan receptors on human neutrophils initiates phagocytosis and leukotriene B4 production. J Immunol 1988; 141:3170-6.
12. Sanguedolce MV, Capo C, Bongrand P, Mege JL. Zymosan-stimulated tumor necrosis factor-α production by human monocytes, Down-modulation by phorbol ester. J Immunol 1992; 148:2229-36.
13. Au BT, Williams TJ, Collins PD. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. J Immunol 1994; 152:5411-9.
14. Mencacci A, Torosantucci A, Spaccapelo R, Romani L, Bistoni F, Cassone A. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun 1994; 62:5353-60.
15. Layton GT, Harris SJ, Gearing AJ et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3: Ty-virus-like particles. J Immunol 1993; 151:1097-107.
16. Takahashi H, Germain RN, Moss B, Berzofsky JA. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II- restricted help for itself. J Exp Med 1990; 171:571-6.
17. Okuda K, Twining SS, David CS, Atassi MZ. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J Immunol 1979; 123:182-8.
18. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19:739-44.
19. 0 (α α) protein is mainly located in the heart and the striated muscles. Biochim Biophys Acta 1985; 842:146-50.
20. Tanaka Y. Immunohistochemical study of human lymphoid tissues with monoclonal antibodies against S-100 protein subunits. Virchows Arch A 1986; 410:125-32.
21. Okimura T, Ogawa M, Yamauchi T. Stress and immune responses. III. Effect of restraint stress on delayed type hypersensitivity (DTH) response, natural killer (NK) activity and phagocytosis in mice. Jpn J Pharmacol 1986; 41:229-35.
22. Miura T, Ohno N, Miura NN, Adachi Y, Shimada S, Yadomae T. Antigen-specific response of murine immune system toward a yeast β-glucan preparation, zymosan. FEMS Immunol Med Microbiol 1999; 24:131-9.
23. Maraskovsky E, Chen WF, Shortman K. IL-12 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143:1210-4.
24. Tsuji T, Hamajima K, Fukushima J et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158:4008-13.
25. Ezekowitz RA, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med 1984; 159:244-60.
26. Stout RD, Bottomly K, Antigen-specific activation of effector macrophages by IFN-γ producing (Th1) T cell clones. Failure of IL- 4 producing (Th2) T cell clones to activate effector functions in macrophages. J Immunol 1989; 142:760-5.
27. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein, Cell 1988; 52:269-79.
28. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91:295-8.
29. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11:443-51.
30. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401:811-5.
31. Yang RB, Mark MR, Gray A et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395:284-8.
32. Magram J, Connaughton SE, Warrior RR et al. IL-12-deficient mice are defective in IFN-γ production and type-1 cytokine responses. Immunity 1996; 4:471-81.
33. + T cells from αβ-TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ dependent. Int Immunol 1993; 5:1119-28.
34. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk,) sing. Carbohydr Polym 1969; 222:687-8.
35. Seljelid R, Bogwald J, Hoffman J, Larm O. A soluble β-1,3-D-glucan derivative potentiates the cytostatic and cytolytic capacity of mouse peritoneal macrophages in vitro. Immunopharmacology 1984; 7:69-73.
36. Scaringi L, Marconi P, Boccanera M, Tissi L, Bistoni F, Cassone A. Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J Gen Microbiol 1988; 134:1265-74.
37. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. The role of tumor antigen specific delayed-type hypersensitivity responses in eradication tumors by lentinan. Biothrapy 1993; 7:345.
38. Vetvicka V, Thornton BP, Ross GD, Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996; 98:50-61.
39. Matsuoka H, Seo Y, Wakasugi H, Saito T, Tomoda H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res 1997; 17:2751-5.
40. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. B-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999; 163:3045-52.
41. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
42. Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency-virus type 1. Proc Natl Acad Sci USA 1993; 90:4156-60.